ProQR Therapeutics N.V. PRQR
1.37 USD +0.05 (+3.79%)
Nov 3, 2026, 3:37 PM EST
1.33 Day range 1.39
1.20 52-week range 2.65
- YTD
- -32.18%
- 1 year
- -47.10%
News
benzinga.com ProQR Therapeutics To Present Data On Its AX-0810, AX-0811 At The Liver Meeting 2026, Nature Conferences RNA ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing…
globenewswire.com ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative…
defenseworld.net ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Consensus Price Target of $7.60 According to Analysts ProQR Therapeutics N.V. (NASDAQ: PRQR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the stock, Marketbeat…
marketbeat.com ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease ProQR Therapeutics NASDAQ: PRQR said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid…
benzinga.com HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8 HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.
seekingalpha.com ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
globenewswire.com ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor Appointments support ProQR's strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipeline AX-0811, the first ProQR program identified…
globenewswire.com ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative…
globenewswire.com ProQR to Participate in Upcoming Investor Conferences in September 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
seekingalpha.com ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts I initiate ProQR Therapeutics N.V. with a Buy rating, driven by strong initial human proof-of-concept for its Axiomer RNA editing platform. The company's AX-0810 achieved 8-fold serum bile acid…
benzinga.com Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losses in Q4 and exit of Gucci Beauty license.
benzinga.com B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8 B of A Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Buy rating and announces Price Target of $8.
benzinga.com ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 25 percent increase over losses of…
globenewswire.com ProQR Announces Second Quarter 2026 Operating and Financial Results LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative…
defenseworld.net Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR) ProQR Therapeutics (NASDAQ: PRQR - Get Free Report) and Artiva Biotherapeutics (NASDAQ: ARTV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
defenseworld.net ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of “Moderate Buy” from Analysts ProQR Therapeutics N.V. (NASDAQ: PRQR - Get Free Report) has received an average rating of "Moderate Buy" from the six brokerages that are currently covering the firm, MarketBeat.com reports. One…
seekingalpha.com ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis ProQR Therapeutics (PRQR) has transitioned its RNA editing platform from preclinical promise to demonstrated human pharmacological activity, notably with AX-0810's Phase 1 target engagement data.…
benzinga.com Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6 Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and raises the price target from $5 to $6.
benzinga.com ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday Top analysts change outlook on top names: BMO, Chardan, Rosenblatt, Susquehanna, Evercore, Deutsche Bank, Baird, Stephens & Co.- benzinga.com Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3 Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $4 to $3.
benzinga.com Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase.- benzinga.com ProQR Therapeutics Prices Registered Direct Offering Of 27,624,310 Shares At $1.81 Per Share For Total Gross Proceeds Of ~$50M; Also Enters Private Placement With Lilly For ~5.1M Shares At Same Offer Price ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing…
globenewswire.com ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives…- benzinga.com ProQR Therapeutics Announces Data From Its Ongoing Phase 1 Clinical Study Of AX-0810 Investigational Axiomer RNA Editing Oligonucleotide; Sees Target Engagement On All Key Biomarkers Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated…
globenewswire.com ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated…- benzinga.com ProQR Therapeutics Q1 EPS $(0.15), Inline, Sales $2.381M Miss $5.530M Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.10) per share from the same…
globenewswire.com ProQR Announces First Quarter 2026 Operating and Financial Results AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422…
globenewswire.com ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
zacks.com Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
globenewswire.com ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative…- benzinga.com ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Nebula ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com ProQR Therapeutics Q4 EPS $(0.09) Misses $(0.08) Estimate, Sales $5.458M Miss $8.550M Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 10 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com ProQR Therapeutics Q3 EPS $(0.10), Inline, Sales $2.882M Miss $8.550M Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the…- benzinga.com Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
- benzinga.com ProQR Therapeutics Gets European Medicines Agency's Committee's Authorization For Clinical Trial Application For Phase 1 Trial Of AX-0810 To Treat Clerosing Cholangitis, Biliary Atresia ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
- benzinga.com ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate, Sales $4.327M Miss $4.408M Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of…
benzinga.com ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of…
benzinga.com Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Overweight and maintains $8 price target.- benzinga.com JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Market Outperform and maintains $8 price target.
benzinga.com Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9 Oppenheimer analyst Andreas Argyrides maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and lowers the price target from $15 to $9.- benzinga.com Evercore ISI Group Initiates Coverage On ProQR Therapeutics with Outperform Rating, Announces Price Target of $5 Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Outperform rating and announces Price Target of $5.
- benzinga.com ProQR Therapeutics Appoints Dennis Hom As CFO LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies…
- benzinga.com Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12 HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $10 to $12.